Copyright
©The Author(s) 2018.
World J Hepatol. Feb 27, 2018; 10(2): 186-212
Published online Feb 27, 2018. doi: 10.4254/wjh.v10.i2.186
Published online Feb 27, 2018. doi: 10.4254/wjh.v10.i2.186
Assay | Distributor | Technology | Detection limits (IU/mL) | Genotypes | Approval status |
Qualitative HCV RNA detection assays | |||||
AmplicorTM HCV 2.0 | Roche molecular Systems | PCR | 50 | All | FDA, CE |
VersantTM HCV | Siemens Medical Solutions Diagnostics | TMA | 5-10 | All | FDA, CE |
Quantitative HCV RNA detection | |||||
AmplicorTM HCV Monitor 2.0 | Roche molecular Systems | PCR | 500 to approximately 5.105 | All | CE |
HCV SuperQuantTM | National Genetics institute | PCR | 30 to 107 | All | U.S only |
VersantR HCV RNA 3.0 | Siemens Medical Solutions Diagnostics | bDNA | 615 to 8.106 | All | FDA, CE |
CobasR AmpliPrep/High pure system/CobasR TaqManR | Roche molecular Systems | Real-time PCR | 15 to 107 | All | FDA, CE |
Abbot RealTimeTM HCV | Abbot Diagnostics | Real-time PCR | 10 to 107 | All | FDA, CE |
Artus HCV QS-RGQ assay | Qiagen | Real-time PCR | 34 to 108 | All | CE |
VersantRR HCV 1.0 kPCR assay | Siemens | Real-time PCR | 10 to approximately 107 | - | CE |
- Citation: Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol 2018; 10(2): 186-212
- URL: https://www.wjgnet.com/1948-5182/full/v10/i2/186.htm
- DOI: https://dx.doi.org/10.4254/wjh.v10.i2.186